Provided by Tiger Trade Technology Pte. Ltd.

Exelixis

58.03
-0.3050-0.52%
Volume:433.80K
Turnover:25.10M
Market Cap:14.38B
PE:18.25
High:58.33
Open:58.33
Low:57.45
Close:58.33
52wk High:59.72
52wk Low:33.76
Shares:247.78M
Float Shares:214.00M
Volume Ratio:0.35
T/O Rate:0.20%
Dividend:- -
Dividend Rate:- -
EPS(TTM):3.18
EPS(LYR):2.78
ROE:44.39%
ROA:23.97%
PB:7.80
PE(LYR):20.87

Loading ...

Exelixis Outlook FY Revenue USD 2,500-2,550 Million

THOMSON REUTERS
·
Aug 06

Exelixis Q2 Adjusted EPS USD 0.91 VS. Ibes Estimate USD 0.79

THOMSON REUTERS
·
Aug 06

Exelixis Inc Expected to Post Earnings of 79 Cents a Share - Earnings Preview

Reuters
·
Aug 04

Earning Preview: Exelixis Q2 revenue is expected to increase by 10.71%, and institutional views are optimistic

Earnings Agent
·
Jul 29

Exelixis (EXEL) Stock Still Looks Like A Bargain On Earnings

Simply Wall St.
·
Jul 27

EXEL Industries Hit by Slump in Agricultural and Industrial Demand in Q3

TIPRANKS
·
Jul 24

Exelixis is Maintained at Equal-weight by Morgan Stanley

Dow Jones
·
Jul 24

Press Release: Exelixis to Release Second Quarter 2026 Financial Results on Wednesday, August 5, 2026

Dow Jones
·
Jul 23

Exelixis Schedules Quarterly Results Release and Investor Call

Reuters
·
Jul 23

Exelixis, Inc. : Barclays Raises Target Price to $49 from $45

THOMSON REUTERS
·
Jul 14

Exelixis price target raised to $49 from $45 at Barclays

TIPRANKS
·
Jul 14

Barclays Remains a Hold on Exelixis (EXEL)

TIPRANKS
·
Jul 14

Exelixis is Maintained at Equal-weight by Wells Fargo

Dow Jones
·
Jul 13

Exelixis price target raised to $56 from $54 at Truist

TIPRANKS
·
Jul 07

Exelixis is Maintained at Hold by Truist Securities

Dow Jones
·
Jul 07

RBC Capital Adjusts Exelixis Price Target to $46 From $43, Maintains Sector Perform Rating

MT Newswires Live
·
Jul 07

Is Exelixis (EXEL) Undervalued Or Already Priced In On Its Oncology Growth Story?

Simply Wall St.
·
Jul 05

Sector Update: Healthcare Stocks Gain Thursday Afternoon

MT Newswires Live
·
Jul 03

Exelixis Faces Balanced Risk-Reward Ahead of Key Catalysts, UBS Says

MT Newswires Live
·
Jul 03

UBS Adjusts Price Target on Exelixis to $52 From $43, Maintains Neutral Rating

MT Newswires Live
·
Jul 02